(Q39189394)

English

Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.

scientific article published on 23 December 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

0 references

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Arnoud J Templeton

3

object named as

A J Templeton

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Z Zafeiriou

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

D Bianchini

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

R Ferraldeschi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

A Bahl

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

L Shen

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Z Su

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

O Sartor

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

J S de Bono

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

23 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

750-755

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

21 January 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

21 January 2018

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

21 January 2018

Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

21 January 2018

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

21 January 2018

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

21 January 2018

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

21 January 2018

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

21 January 2018

Reporting recommendations for tumor marker prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

21 January 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

21 January 2018

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

21 January 2018

Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39189394&oldid=1521636968"